{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Guadecitabine+%28SGI-110%29",
    "query": {
      "intervention": "Guadecitabine (SGI-110)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 28,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Guadecitabine+%28SGI-110%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T13:19:31.981Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03179943",
      "title": "Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Guadecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2017-11-27",
      "completion_date": "2022-07",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-09-27T13:19:31.981Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03179943"
    },
    {
      "nct_id": "NCT02892318",
      "title": "A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Guadecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2016-10-31",
      "completion_date": "2019-12-12",
      "has_results": false,
      "last_update_posted_date": "2020-03-13",
      "last_synced_at": "2026-09-27T13:19:31.981Z",
      "location_count": 8,
      "location_summary": "Duarte, California • New Haven, Connecticut • New York, New York + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02892318"
    },
    {
      "nct_id": "NCT03576963",
      "title": "Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Adenocarcinoma",
        "CpG Island Methylator Phenotype",
        "Metastatic Microsatellite Stable Colorectal Carcinoma",
        "Refractory Colorectal Carcinoma",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IVA Colorectal Cancer AJCC v8",
        "Stage IVB Colorectal Cancer AJCC v8",
        "Stage IVC Colorectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Guadecitabine",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-01-30",
      "completion_date": "2023-01-30",
      "has_results": false,
      "last_update_posted_date": "2021-04-05",
      "last_synced_at": "2026-09-27T13:19:31.981Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Newport Beach, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03576963"
    },
    {
      "nct_id": "NCT03603964",
      "title": "Guadecitabine Extension Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myeloid Dysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Guadecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astex Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2018-07-18",
      "completion_date": "2021-10-04",
      "has_results": true,
      "last_update_posted_date": "2024-08-27",
      "last_synced_at": "2026-09-27T13:19:31.981Z",
      "location_count": 5,
      "location_summary": "Buffalo, New York • Durham, North Carolina • Columbus, Ohio + 2 more",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03603964"
    },
    {
      "nct_id": "NCT02131597",
      "title": "Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High Risk Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Guadecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2014-11-10",
      "completion_date": "2024-07-25",
      "has_results": true,
      "last_update_posted_date": "2025-07-17",
      "last_synced_at": "2026-09-27T13:19:31.981Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02131597"
    },
    {
      "nct_id": "NCT03165721",
      "title": "A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Paraganglioma",
        "Gastrointestinal Stromal Tumors",
        "Carcinoma, Renal Cell",
        "Renal Neoplasms",
        "Pheochromocytoma"
      ],
      "interventions": [
        {
          "name": "SGI-110 (guadecitabine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "12 Years to 99 Years"
      },
      "enrollment_count": 9,
      "start_date": "2017-08-16",
      "completion_date": "2020-02-24",
      "has_results": true,
      "last_update_posted_date": "2026-02-18",
      "last_synced_at": "2026-09-27T13:19:31.981Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03165721"
    },
    {
      "nct_id": "NCT03257761",
      "title": "Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Extrahepatic Bile Duct Adenocarcinoma, Biliary Type",
        "Gallbladder Adenocarcinoma, Biliary Type",
        "Metastatic Pancreatic Adenocarcinoma",
        "Recurrent Cholangiocarcinoma",
        "Recurrent Gallbladder Carcinoma",
        "Recurrent Hepatocellular Carcinoma",
        "Recurrent Intrahepatic Cholangiocarcinoma",
        "Recurrent Pancreatic Carcinoma",
        "Stage III Gallbladder Cancer AJCC V7",
        "Stage III Hepatocellular Carcinoma AJCC v7",
        "Stage III Intrahepatic Cholangiocarcinoma AJCC v7",
        "Stage III Pancreatic Cancer AJCC v6 and v7",
        "Stage IIIA Gallbladder Cancer AJCC v7",
        "Stage IIIA Hepatocellular Carcinoma AJCC v7",
        "Stage IIIB Gallbladder Cancer AJCC v7",
        "Stage IIIB Hepatocellular Carcinoma AJCC v7",
        "Stage IIIC Hepatocellular Carcinoma AJCC v7",
        "Stage IV Gallbladder Cancer AJCC v7",
        "Stage IV Hepatocellular Carcinoma AJCC v7",
        "Stage IV Pancreatic Cancer AJCC v6 and v7",
        "Stage IVA Gallbladder Cancer AJCC v7",
        "Stage IVA Hepatocellular Carcinoma AJCC v7",
        "Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7",
        "Stage IVB Gallbladder Cancer AJCC v7",
        "Stage IVB Hepatocellular Carcinoma AJCC v7",
        "Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7",
        "Unresectable Gallbladder Carcinoma",
        "Unresectable Pancreatic Carcinoma"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Guadecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2018-02-07",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-09-27T13:19:31.981Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Newport Beach, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03257761"
    },
    {
      "nct_id": "NCT01966289",
      "title": "SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "CY",
          "type": "DRUG"
        },
        {
          "name": "GVAX",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SGI-110",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2014-04-14",
      "completion_date": "2020-06-06",
      "has_results": false,
      "last_update_posted_date": "2021-03-30",
      "last_synced_at": "2026-09-27T13:19:31.981Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01966289"
    },
    {
      "nct_id": "NCT03075826",
      "title": "A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "SGI-110",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2016-03-15",
      "completion_date": "2021-03-31",
      "has_results": true,
      "last_update_posted_date": "2022-05-05",
      "last_synced_at": "2026-09-27T13:19:31.981Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03075826"
    },
    {
      "nct_id": "NCT03913455",
      "title": "Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer",
        "Extensive-stage Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Guadecitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shadia Jalal, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2019-06-06",
      "completion_date": "2022-02-02",
      "has_results": true,
      "last_update_posted_date": "2023-12-20",
      "last_synced_at": "2026-09-27T13:19:31.981Z",
      "location_count": 4,
      "location_summary": "Indianapolis, Indiana • Muncie, Indiana • Charlottesville, Virginia + 1 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Muncie",
          "state": "Indiana"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03913455"
    }
  ]
}